Stock Markets April 13, 2026 06:57 AM

IDEAYA Shares Jump After Darovasertib Combination Meets Primary Endpoint in Registrational Trial

OptimUM-02 shows statistically significant progression-free survival benefit in first-line metastatic uveal melanoma; company targets NDA submission in H2 2026

By Priya Menon IDYA
IDEAYA Shares Jump After Darovasertib Combination Meets Primary Endpoint in Registrational Trial
IDYA

IDEAYA Biosciences shares climbed 27% on Monday after topline results from the Phase 2/3 OptimUM-02 trial demonstrated a statistically significant median progression-free survival advantage for darovasertib combined with crizotinib versus investigator choice of therapy in first-line metastatic uveal melanoma. The trial met its primary endpoint, and IDEAYA plans a New Drug Application submission to the U.S. Food and Drug Administration in the second half of 2026 to support accelerated approval.

Key Points

  • OptimUM-02 met its primary endpoint with a statistically significant improvement in median PFS: 6.9 months for darovasertib plus crizotinib versus 3.1 months for investigator choice (hazard ratio 0.42; 95% CI: 0.30, 0.59).
  • The trial enrolled 313 HLA-A02:01-negative patients; 210 received the darovasertib combination and 103 received investigator choice therapy, predominantly ipilimumab plus nivolumab (76%) or pembrolizumab (24%).
  • IDEAYA plans an NDA submission to the U.S. FDA in the second half of 2026 to support accelerated approval, with full OptimUM-02 data scheduled for presentation at a major medical conference in 2026.

Overview

Shares of IDEAYA Biosciences (NASDAQ: IDYA) rose 27% on Monday following the release of topline data from the companys Phase 2/3 registrational study, OptimUM-02. The trial evaluated darovasertib in combination with crizotinib as first-line therapy for patients with metastatic uveal melanoma who are HLA-A02:01-negative.


Primary endpoint and efficacy results

The OptimUM-02 study met its primary endpoint, demonstrating a statistically significant improvement in median progression-free survival (PFS). Patients randomized to the darovasertib plus crizotinib arm achieved a median PFS of 6.9 months compared with 3.1 months for those who received investigator choice of therapy. The reported hazard ratio was 0.42 with a 95% confidence interval of 0.30 to 0.59.


Trial population and comparator details

The study enrolled 313 patients with HLA-A02:01-negative metastatic uveal melanoma. Of those, 210 patients were assigned to the darovasertib combination, while 103 patients received investigator choice of therapy. Within the investigator choice arm, 76% of patients were treated with ipilimumab plus nivolumab and 24% received pembrolizumab.


Secondary endpoints and additional outcomes

For the secondary endpoint of overall response rate (ORR), the darovasertib combination produced a 37.1% ORR compared with 5.8% for investigator choice of therapy. According to a blinded independent central review, the darovasertib combination reduced the risk of disease progression by 58%.


Survival, safety, and next steps

Overall survival data from OptimUM-02 are not yet mature. The company reported an early trend toward improved overall survival in the darovasertib combination arm, but full conclusions await more mature follow-up. The treatment regimen was described as generally well tolerated, with a manageable safety profile. The most common Grade 3 or higher treatment-emergent adverse events included diarrhea, syncope, and hypotension.

IDEAYA intends to submit a New Drug Application to the U.S. Food and Drug Administration in the second half of 2026 seeking accelerated approval. The company also plans to present the full OptimUM-02 dataset at a major medical conference in 2026. The trial was conducted in collaboration with Servier.


Implications for markets and stakeholders

The topline readout triggered a strong market reaction reflected in the intraday share move. For investors and participants in the biotech and pharmaceutical sectors, the results will be watched closely as the program advances through regulatory review. Clinicians and patients with metastatic uveal melanoma will await the detailed data presentation later in 2026.

Risks

  • Overall survival data are not yet mature, leaving the long-term benefit of the darovasertib combination uncertain - impacts clinical and regulatory assessment in oncology and biotech sectors.
  • Regulatory approval is not guaranteed despite positive topline PFS and ORR results; the FDA review process for accelerated approval introduces timing and outcome risk - relevant to investors and the pharmaceutical industry.
  • Safety signals include Grade 3 or higher treatment-emergent adverse events such as diarrhea, syncope, and hypotension, which may affect the regimen's tolerability and regulatory evaluation - relevant to clinicians, patients, and drug developers.

More from Stock Markets

National Healthcare Properties Targets $1.1 Billion Valuation in U.S. IPO Apr 13, 2026 Revolution Medicines Shares Soar After Phase 3 Pancreatic Cancer Results Apr 13, 2026 Allogene Shares Jump After Interim ALPHA3 Results Show Large MRD Benefit Apr 13, 2026 Pershing Square Opens Roadshow for Paired U.S. Listings Apr 13, 2026 Goldman Shares Slide Despite Strong Q1 Results as Bank Stocks Retreat Apr 13, 2026